用白细胞粘附抑制法鉴定HBV-TF特异免疫活性

选用白细胞粘附抑制试验来鉴定乙肝特异性转移因子(HBV-TF)免疫活性。实验结果表明:经HBV-TF致敏的淋巴细胞与乙肝抗原(HBV-Ag)孵育后,显示出明显的粘附抑制活性,而非特异性转移因子(TFn)致敏淋巴细胞与乙肝抗原孵育、HBV-TF致敏淋巴细胞与甲肝抗原(HAV-Ag)孵育或HBV-TF致敏淋巴细胞与1640液(代替抗原液)孵育时均不能表现出这种抑制作用,说明HBV-TF具有抗原特异性免疫活性。实验证明,本法是体外鉴定HBV-TF免疫活性简便易行的方法。

特异性转移因子对卵巢癌患者、宫颈癌患者白细胞粘附抑制率的影响

目的 :观察特异性转移因子在化疗的卵巢癌患者和放化疗的宫颈癌患者体内生物学活性。方法 :对实验组化疗的卵巢癌患者和放化疗的宫颈癌患者加用特异性转移因子免疫治疗 ,对照组不用特异性转移因子治疗 ,利用白细胞粘附抑制试验测外周血白细胞。结果 :实验组白细胞粘附抑制试验显著高于对照组 (P <0 .0 5 )。结论 :特异性转移因子对化疗的卵巢癌患者和放化疗的宫颈癌患者 。

特异性转移因子对卵巢癌患者淋巴细胞转化和白细胞粘附抑制试验的影响

目的 观察特异性转移因子在化疗的卵巢癌患者的体内生物学活性。方法 对化疗的卵巢癌患者用特异性转移因子免疫治疗。利用淋巴细胞转化试验及白细胞粘附抑制试验检测外周血淋巴细胞、白细胞。结果 实验组淋巴细胞转化率 ,有 3 4 4%显著高于对照组 (P <0 0 1)。实验组白细胞粘附抑制试验显著高于对照组 (P <0 0 5 )。结论 山羊来源的特异性转移因子对化疗卵巢癌患者 ,有促进淋巴细胞转化率及白细胞粘附抑制率作用。

胃癌特异性转移因子体外白细胞粘附抑制活性研究

利用白细胞粘附抑制实验， 对胃癌特异性转移因子（ Ｇ Ｔ Ｆ） 的生物学活性及其作用特异性进行了研究。结果表明胃癌特异性转移因子在体外具有白细胞粘附抑制能力， 并且这一生物学活性具有抗原特异性（ Ｐ＜ ００１ ） 。

免疫绵羊不同器官提取抗乙肝免疫核糖核酸活性比较

目的：探索最适用以提取抗乙肝iRNA的器官。方法：用白细胞粘附抑制法对不同器官所提取抗乙肝iRNA活性进行比较。结果：我们发现，淋巴结所提取抗乙肝iRNA活性最高，脾脏次之，肝脏最低。结论：经过试验证明，为了获得高活性的抗乙肝iRNA，应选择免疫反应性强的器官，即淋巴结或脾脏。

Correlation of matrix metalloproteinase－2, －9, tissue inhibitor－1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis

This study aimed to explore the molecular mechanism in tumor invasion and metastasis. The expression of matrix metalloproteinase 2, 9 (MMP 2, MMP 9), tissue inhibitor 1 of matrix metalloproteinase (TIMP 1), cell adhesion molecule 44 variant 6 (CD44v6), HER2/neu and p53 was investigated in 154 patients with head and neck squamous cell carcinoma (SCC) by ABC and ImmunoMax immunohistochemical method. Their clinical relevance and correlation were analysed. The expression of MMP 2, MMP 9, TIMP 1, CD44v6, HER2/neu and p53 was found in cancer cells in 87.01%, 85.71%, 68.18%, 98.05%, 55.19% and 50.65% cases respectively. Linear regression and correlation analysis revealed that there was close positive relationship ( P <0.05) between the expression of MMP 2 and MMP 9, TIMP 1 and CD44v6, HER2/neu and MMP 9, MMP 2 and p53. Up regulation of MMP 2 was accompanied by advanced T stage ( P <0.01) . There was also a trend of MMP 2 expression being related with tumor metastasis. Increased expression of HER2/neu was found in patients with tumor recurrence( P <0.05). The expression of TIMP 1 was higher in laryngeal cancer than that in pharyngeal cancer, and higher in keratinizing and non keratinizing SCC than that in basaloid SCC( P <0.05). These findings suggested that MMP 2 and MMP 9, HER2/neu and MMP 9, MMP 2 and p53 had a coordinate function in aggression of tumor; that MMP 2 had a more important function than MMP 9 in tumor invasion and metastasis; and that HER2/neu might serve as a biomarker for poor prognosis in HNSCC.